Eduardo Mondlane University
12
2
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Role: collaborator
The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis
Role: collaborator
Expanding Health Systems Research to Optimize Hypertension Care Cascade in HIV-Infected Individuals in Mozambique
Role: lead
Rice Technologies for Cervical Cancer Screening and Diagnosis
Role: collaborator
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Role: collaborator
A Prospective Cohort With Patient Navigation as an Intervention for Breast Cancer Patients
Role: collaborator
Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries
Role: collaborator
Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study
Role: collaborator
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
Role: collaborator
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
Role: collaborator
Systems Analysis and Improvement to Optimize pMTCT
Role: collaborator
The Pan African Pulmonary Hypertension Cohort Study
Role: collaborator
All 12 trials loaded